Zes 30 mg Capsule 10s

Side Effects of Zes 30 mg Capsule 10s

Increased risk of Clostridium difficile-associated diarrhoea (CDAD) and osteoporosis-related fractures. Diarrhoea, abdominal pain, nausea, vomiting, flatulence, constipation, headache, dry mouth, peripheral oedema, dizziness, sleep disturbances, fatigue, paraesthesia, arthralgia, myalgia, rash, pruritus, pancreatitis, glossitis, tremor, anorexia, restlessness, impotence, petechiae, purpura. Rare or very rarely, taste disturbance, stomatitis, hepatitis, jaundice, hypersensitivity reactions (e.g. bronchospasm), fever, depression, hallucinations, confusion, gynaecomastia, interstitial nephritis, hyponatraemia, hypomagnesaemia, blood disorders (e.g. leucopenia, leucocytosis, pancytopenia, thrombocytopenia), visual disturbances, sweating, photosensitivity, alopecia; colitis, increased serum cholesterol or triglycerides. Potentially Fatal: Anaphylaxis, Stevens-Johnson syndrome and toxic epidermal necrolysis.

Drug Interactions

Increased risk of hypomagnesaemia w/ diuretics and digoxin. May decrease plasma concentration of erlotinib, dasatinib and lapatinib. May decrease the bioavailability of itraconazole and ketoconazole. May increase plasma concentration of cilostazol and methotrexate. Reduced bioavailability w/ antacids and sucralfate. Potentially Fatal: May decrease serum levels and pharmacological effects of rilpivirine and atazanavir.

Contraindications

Concomitant use w/ rilpivirine and atazanavir.

Mechanism of Action

Lansoprazole is a substituted benzimidazole, and is also known as PPI due to its property to block the final step of acid secretion by inhibiting H+/K+ ATPase enzyme system in gastric parietal cell. Both basal and stimulated acid are inhibited. Onset: Oral: 1-3 hr. Duration: Oral: >1 day. Absorption: Rapidly absorbed from the GI tract (oral). Reduced absorption and bioavailability (approx 50%) w/ food. Bioavailability: ≥80%. Time to peak plasma concentration: Approx 1.5-2 hr. Distribution: Volume of distribution: 14-18 L. Plasma protein binding: Approx 97%. Metabolism: Hepatic metabolism via CYP2C19 isoenzyme to form 5-hydroxyl-lansoprazole and CYP3A4 to form lansoprazole sulfone. Excretion: Mainly in faeces via the bile; 15-30% of a dose via urine. Plasma elimination half-life: Approx 1-2 hr.

Special Precautions

Gastric malignancy should be ruled out. Hepatic impairment. Pregnancy and lactation. Monitoring Parameters Monitor Mg levels prior to initiation and periodically during prolonged use.

How to Use

Take orally with food and water, as directed by your physician.

How to Store

Keep in a cool, dry place away from sunlight and moisture.

Safety Concerns

• Alcohol: Avoid during treatment.
• Breastfeeding: Not recommended.
• Pregnancy: Contraindicated.
• Liver/Kidney: Use with caution.

Content Disclaimer

This content is for educational purposes only. Please consult your doctor before use.